Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade D 177.84 1.19% 2.09
SHPG closed up 1.19 percent on Thursday, April 27, 2017, on 66 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: May 2

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical SHPG trend table...

Date Alert Name Type % Chg
Apr 27 Crossed Above 50 DMA Bullish 0.00%
Apr 27 Stochastic Reached Overbought Other 0.00%
Apr 26 Fell Below 50 DMA Bearish 1.19%
Apr 25 Crossed Above 50 DMA Bullish 0.66%
Apr 24 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.21%
Apr 21 NR7 Range Contraction 3.43%
Apr 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.43%
Apr 19 Stochastic Reached Oversold Other 5.06%
Apr 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.50%
Apr 13 Shooting Star Candlestick Bearish 3.91%

Older signals for SHPG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 209.22
52 Week Low 161.09
Average Volume 993,856
200-Day Moving Average 181.3465
50-Day Moving Average 176.7988
20-Day Moving Average 173.0115
10-Day Moving Average 173.165
Average True Range 2.6807
ADX 16.13
+DI 28.51
-DI: 21.85
Chandelier Exit (Long, 3 ATRs) 170.5579
Chandelier Exit (Short, 3 ATRs) 176.3021
Upper Bollinger Band 178.9546
Lower Bollinger Band 167.0684
Percent B (%b) 0.91
Bandwidth 0.068702